Related Experiment Video
Updated: Jun 6, 2026

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
Published on: January 24, 2020
Clinical application of cytokine-induced killer cells in cancer immunotherapy
Farzaneh Ghorbani1, Hossein Abbaszadeh1, Yahya Yahyavi1,2
1Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Cytokine-induced killer (CIK) cells exhibit potent antitumor activity with reduced dependence on strict MHC compatibility, mediated by a combination of T-cell receptor (TCR)-dependent recognition and natural killer (NK)-like, MHC-unrestricted cytotoxicity. This narrative review synthesizes evidence from clinical trial evaluations, including 48 published studies. We examine strategies to enhance CIK function, such as engineering, combination with checkpoint inhibitors, and co-administration with dendritic cells. CIK cell therapy effectively reduces post-treatment recurrence in the adjuvant setting and enhances chemotherapy outcomes in advanced disease, significantly improving key survival metrics across multiple cancers. A detailed analysis is conducted of ongoing challenges, such as immunosuppressive conditions in tumor microenvironments, limited in vivo durability, product variability, and choosing the best treatment plans. Future advancements in translation depend on establishing standardized manufacturing procedures, developing treatment algorithms guided by precision biomarkers, and validating next-generation engineered CIK cell products in clinical settings.
Cytokine-induced killer (CIK) cells exhibit potent antitumor activity with reduced dependence on strict MHC compatibility, mediated by a combination of T-cell receptor (TCR)-dependent recognition and natural killer (NK)-like, MHC-unrestricted cytotoxicity. This narrative review synthesizes evidence from clinical trial evaluations, including 48 published studies. We examine strategies to enhance CIK function, such as engineering, combination with checkpoint inhibitors, and co-administration with dendritic cells. CIK cell therapy effectively reduces post-treatment recurrence in the adjuvant setting and enhances chemotherapy outcomes in advanced disease, significantly improving key survival metrics across multiple cancers. A detailed analysis is conducted of ongoing challenges, such as immunosuppressive conditions in tumor microenvironments, limited in vivo durability, product variability, and choosing the best treatment plans. Future advancements in translation depend on establishing standardized manufacturing procedures, developing treatment algorithms guided by precision biomarkers, and validating next-generation engineered CIK cell products in clinical settings.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

